Archives
-
Journal of Bone Marrow Transplantation and Cellular Therapy
Vol. 3 No. suppl1 (2022)Proceedings of XXVI Anual Meeting of Brazilian Society of Bone Marrow Transplantation and Cellular Therapy
-
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Vol. 3 No. 1 (2022)SBTMO Cell Therapy Technical Manual: Part I
-
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Vol. 2 No. 4 (2021)Consensus Guidelines for Pedriatric Hematopoietic Stem Cell Transplantation from the Brazilian Society for Blood and Marrow Transplantation and Cellular Therapy
-
Journal of Bone Marrow Transplantation and Cellular Therapy
Vol. 2 No. 1 (2021)Consensus Guidelines for hematopoietic stem cell transplantation from the Brazilian Society for Blood and Marrow Transplantation and Cellular Therapy
-
Journal of Bone Marrow Transplantation and Cellular Therapy
Vol. 1 No. 4 (2020)In this edition - Proceedings of 2020 Anual Meeting of the Brazilian Society of Bone Marrow Transplantation
-
Journal of Bone Marrow Transplantation and Cellular Therapy
Vol. 1 No. 2 (2020)We present the first edition of 2019 (Vol. 41. Num. 1. | Jan. to March) of the Hematology, Transfusion and Cell Therapy magazine.
One of the review articles is the Analysis of Expansion Mesenchymal Stromal in Patients with low risk myelodysplastic Syndrome.
The study aims to evaluate the expansion of mesenchymal stromal cells (MSCs) and the expression of p53 protein in patients with SMD, low risk, according to the International Prognostic System (IPSS), in order to demonstrate the importance of these evaluations also diagnostics.
-
Journal of Bone Marrow Transplantation and Cellular Therapy.
Vol. 1 No. 1 (2020)We present the first edition of 2019 (Vol. 41. Num. 1. | Jan. to March) of the Hematology, Transfusion and Cell Therapy magazine.
One of the review articles is the Analysis of Expansion Mesenchymal Stromal in Patients with low risk myelodysplastic Syndrome.
The study aims to evaluate the expansion of mesenchymal stromal cells (MSCs) and the expression of p53 protein in patients with SMD, low risk, according to the International Prognostic System (IPSS), in order to demonstrate the importance of these evaluations also diagnostics.
